Answers are grounded in this paper and cite their sources.
Multicenter study shows liver stiffness measurement predicts hepatic decompensation in hepatocellular carcinoma patients, suggesting careful treatment selection.
Background/Aims: Hepatic decompensation (HD) following systemic treatment, including atezolizumab+bevacizumab (Atezo/Bev) and tyrosine kinase inhibitors (TKIs), is a critical prognostic event in advanced hepatocellular carcinoma (HCC). This study aims evaluate the predictive utility of liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) for HD incidence post-treatment. Methods: This multicenter study included 396 HCC patients treated who received systemic therapy (Atezo/Bev or TKIs) and underwent VCTE prior to treatment at seven university affiliated hospitals. Clinical outcomes including HD independent of tumor progression, variceal bleeding (VB), overall survival (OS), and progression-free survival (PFS) were assessed. A 25 kPa LSM threshold, based on Baveno VII criteria stratified patients into high and low LSM groups. Results: Of the 396 patients, 176 received Atezo/Bev, while 45 and 175 received lenvatinib and sorafenib, respectively. Treatment distribution was similar between high and low LSM groups (P=0.546). High LSM was associated with increased HD risk (HR=3.00, P < 0.001), VB risk (HR=2.34, P = 0.048), and a trend toward worse OS (HR=1.27, P=0.065). In the low LSM group, Atezo/Bev outperformed TKIs in OS and PFS (P<0.05) without increasing HD risk. In contrast, in the high LSM group, Atezo/Bev and TKIs showed no OS or PFS differences, but Atezo/Bev significantly increased HD and VB risk (P<0.05). A risk score based on four variables (Child-Pugh Score 5, LSM ≥25 kPa, multiple tumors, and high-grade portal vein tumor thrombosis) showed good predictive accuracy for HD at 12 months (AUC=0.832), and effectively identified patients at high risk for HD, VB, and poor survival (P<0.005). Conclusions: LSM by VCTE predicts HD following systemic treatment in advanced HCC. In patients with high LSM, Ate/Bev increases HD risk, warranting careful treatment selection.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: